RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Moleculin Biotech Stock

Moleculin Biotech Revenue 2024

Moleculin Biotech Revenue

0 USD

Ticker

MBRX

ISIN

US60855D2009

WKN

A2QQM0

In 2024, Moleculin Biotech's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Moleculin Biotech Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e130.64-
2028e80.38-
2027e35.9-
2026e--
2025e--
2024e--
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--

Moleculin Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Moleculin Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Moleculin Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Moleculin Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Moleculin Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Moleculin Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Moleculin Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Moleculin Biotech’s growth potential.

Moleculin Biotech Revenue, EBIT and net profit per share

DateMoleculin Biotech RevenueMoleculin Biotech EBITMoleculin Biotech Net Income
2029e130.64 M undefined0 undefined0 undefined
2028e80.38 M undefined34.83 M undefined1.45 M undefined
2027e35.9 M undefined-4.03 M undefined-2.32 M undefined
2026e0 undefined-28.41 M undefined-16.71 M undefined
2025e0 undefined-27.4 M undefined-17 M undefined
2024e0 undefined-26.44 M undefined-21.67 M undefined
20230 undefined-29.63 M undefined-29.77 M undefined
20220 undefined-30.64 M undefined-29.03 M undefined
20210 undefined-22.97 M undefined-15.89 M undefined
20200 undefined-19.74 M undefined-17.36 M undefined
20190 undefined-17.52 M undefined-13.21 M undefined
20180 undefined-15.03 M undefined-11.88 M undefined
20170 undefined-8.65 M undefined-9.81 M undefined
20160 undefined-3.88 M undefined-3.93 M undefined
20150 undefined-465,300 undefined-365,800 undefined
20140 undefined-1.65 M undefined-1.81 M undefined

Moleculin Biotech stock margins

The Moleculin Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Moleculin Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Moleculin Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Moleculin Biotech's sales revenue. A higher gross margin percentage indicates that the Moleculin Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Moleculin Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Moleculin Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Moleculin Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Moleculin Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Moleculin Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Moleculin Biotech Margin History

Moleculin Biotech Gross marginMoleculin Biotech Profit marginMoleculin Biotech EBIT marginMoleculin Biotech Profit margin
2029e0 %0 %0 %
2028e0 %43.34 %1.8 %
2027e0 %-11.21 %-6.46 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %

Moleculin Biotech Aktienanalyse

What does Moleculin Biotech do?

Moleculin Biotech Inc is a biopharmaceutical company based in Houston, Texas, that focuses on the development of innovative cancer therapies. The company was founded in 2015 and has since made significant progress in the research and development of drugs for the treatment of cancer. The company follows an innovative business model consisting of two main divisions: research and development, as well as distribution. Moleculin Biotech focuses on identifying compounds that target specific types and stages of cancer in order to enable personalized cancer treatment. The company currently has several projects in the pipeline, each with the potential to change the way cancer is treated. In the research department, Moleculin Biotech focuses on identifying compounds that target cancer types that have been difficult to treat. The company is dedicated to developing effective drugs that can inhibit cell division in certain types of cancer and stop their growth. The critical goal is to develop medications that selectively attack cancer cells without affecting healthy cells. The distribution department of Moleculin Biotech is responsible for marketing and distributing the developed drugs. The company has a well-established network of distribution partners and agencies that help with the introduction of new products. Moleculin Biotech aims to distribute its products worldwide and continuously expand its patient base. One of Moleculin Biotech's key products is the compound WP1122. This molecule is a prodrug capable of selectively accumulating and acting in cancer cells. As a result, it can be used in combination with other cancer therapies to increase treatment efficacy. The company has already demonstrated the potential of WP1122 in clinical trials and is currently working on its market launch. Another significant product of Moleculin Biotech is Annamycin. This is a chemotherapeutic specifically developed for the treatment of leukemia. The medication has already been tested in clinical trials and proven to be effective. Annamycin has the potential to dramatically change and improve the treatment of leukemia. In addition to these two products, Moleculin Biotech also has MSP-2017 in its portfolio. This anti-tumor drug specifically targets pancreatic cancer and has the potential to increase the survival rate of patients in advanced stages of the disease. MSP-2017 is currently still in the development phase and is expected to enter the market in the coming years. Overall, Moleculin Biotech is a promising company focusing on the development of innovative cancer therapies. The company has the potential to fundamentally change cancer treatment and save the lives of millions of people worldwide. The company is committed to intensifying its research and development activities and continuously expanding its product pipeline. Moleculin Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Moleculin Biotech's Sales Figures

The sales figures of Moleculin Biotech originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Moleculin Biotech’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Moleculin Biotech's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Moleculin Biotech’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Moleculin Biotech stock

How much revenue did Moleculin Biotech generate this year?

Moleculin Biotech has achieved a revenue of 0 USD this year.

How much was the turnover of the company Moleculin Biotech compared to the previous year?

The revenue of Moleculin Biotech has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Moleculin Biotech?

The revenue of Moleculin Biotech is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Moleculin Biotech measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Moleculin Biotech so important for investors?

The revenue of Moleculin Biotech is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Moleculin Biotech pay?

Over the past 12 months, Moleculin Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Moleculin Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Moleculin Biotech?

The current dividend yield of Moleculin Biotech is .

When does Moleculin Biotech pay dividends?

Moleculin Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Moleculin Biotech?

Moleculin Biotech paid dividends every year for the past 0 years.

What is the dividend of Moleculin Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Moleculin Biotech located?

Moleculin Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Moleculin Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Moleculin Biotech from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Moleculin Biotech pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Moleculin Biotech in the year 2023?

In the year 2023, Moleculin Biotech distributed 0 USD as dividends.

In which currency does Moleculin Biotech pay out the dividend?

The dividends of Moleculin Biotech are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Moleculin Biotech

Our stock analysis for Moleculin Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Moleculin Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.